A real world study of Guizhi and Longgu Muli Decoction in children with seasonal allergic rhinitis (Lung and Spleen Deficiency Syndrome)

注册号:

Registration number:

ITMCTR2000003329

最近更新日期:

Date of Last Refreshed on:

2020-05-22

注册时间:

Date of Registration:

2020-05-22

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

桂枝加龙骨牡蛎汤治疗儿童季节性变应性 (肺脾气虚型)鼻炎的真实世界研究

Public title:

A real world study of Guizhi and Longgu Muli Decoction in children with seasonal allergic rhinitis (Lung and Spleen Deficiency Syndrome)

注册题目简写:

English Acronym:

研究课题的正式科学名称:

桂枝加龙骨牡蛎汤治疗儿童季节性变应性 (肺脾气虚型)鼻炎的真实世界研究

Scientific title:

A real world study of Guizhi and Longgu Muli Decoction in children with seasonal allergic rhinitis (Lung and Spleen Deficiency Syndrome)

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000033160 ; ChiMCTR2000003329

申请注册联系人:

古豫蕾

研究负责人:

申琪

Applicant:

Yulei Gu

Study leader:

Qi Shen

申请注册联系人电话:

Applicant telephone:

+86 18337181561

研究负责人电话:

Study leader's telephone:

+86 13838341370

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1148263880@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1543040814@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

河南省郑州市金水区金水路1号河南中医药大学东明校区

研究负责人通讯地址:

河南省郑州市金水区人民路19号河南中医药大学第一附属医院

Applicant address:

Dongming Campus of He'nan University of Traditional Chinese Medicine, 1 Jinshui Road, Jinshui District, Zhengzhou, He'nan, China

Study leader's address:

Dongming Campus of He'nan University of Traditional Chinese Medicine, 1 Jinshui Road, Jinshui District, Zhengzhou, He'nan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

河南中医药大学

Applicant's institution:

He'nan University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020HL-037-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

河南中医药大学第一附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital of He'nan University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/4/30 0:00:00

伦理委员会联系人:

王春芳

Contact Name of the ethic committee:

Chunfang Wang

伦理委员会联系地址:

河南省郑州市金水区人民路19号河南中医药大学第一附属医院

Contact Address of the ethic committee:

The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine, 19 Renmin Road, Jinshui District, Zhengzhou, He'nan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

河南中医药大学第一附属医院

Primary sponsor:

The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

河南省郑州市金水区人民路19号

Primary sponsor's address:

19 Renmin Road, Jinshui District, Zhengzhou, He'nan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南

市(区县):

郑州

Country:

China

Province:

He'nan

City:

Zhengzhou

单位(医院):

河南中医药大学第一附属医院

具体地址:

金水区人民路19号

Institution
hospital:

The First Affiliated Hospital of He'nan University of Traditional Chinese Medicine

Address:

19 Renmin Road, Jinshui District

经费或物资来源:

Source(s) of funding:

self-raised

研究疾病:

变应性鼻炎

研究疾病代码:

Target disease:

allergic rhinitis

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

非随机对照试验

Non randomized control

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.观察桂枝加龙骨牡蛎汤治疗儿童季节性AR的临床疗效和安全性; 2.观察桂枝加龙骨牡蛎汤对肺脾气虚型季节性AR患儿全身症状的改善情况; 3.通过随访评价桂枝加龙骨牡蛎汤对预防儿童季节性AR复发的效果。

Objectives of Study:

1.Clinical efficacy and safety of Guizhi and Longgu Muli Decoction in treating seasonal AR of children were observed; 2.Effect of Guizhi and Longgu Muli Decoction on systemic symptoms of seasonal AR of lung-qi deficiency; 3.Effect of Guizhi and Longgu Muli Decoction on preventing seasonal AR recurrence in children was evaluated by follow-up.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1)符合西医儿童AR的诊断标准。 2)符合中医肺脾气虚型鼻鼽的诊断标准。 3)3岁至14岁,男女不限。 4)属季节性发病的AR患儿。 5)患儿法定监护人明确并知情同意。

Inclusion criteria

1. Meet the diagnostic criteria of Western medicine children AR. 2. It conforms to the diagnostic standard of the deficiency of lung qi and spleen qi. 3. From 3 to 14 years old, male and female are not limited. 4. Children with seasonal AR. 5. The legal guardian of the child is clear and informed.

排除标准:

1)合并有心、脑、肝、肾、消化系统等其他系统严重疾病的患儿。 2)正在合并多种用药或不规范用药,可能影响本研究疗效观察的患儿。

Exclusion criteria:

1. Children with heart, brain, liver, kidney, digestive system and other serious diseases. 2. Children who are in the process of combining multiple drugs or nonstandard drugs, which may affect the efficacy observation of this study.

研究实施时间:

Study execute time:

From 2020-08-01

To      2022-05-31

征募观察对象时间:

Recruiting time:

From 2020-08-01

To      2021-05-31

干预措施:

Interventions:

组别:

桂枝加龙骨牡蛎汤组vs西医常规治疗组

样本量:

725

Group:

Guizhi and Longgu Muli Decoction group vs.traditional western medicine group

Sample size:

干预措施:

干预措施代码:

Intervention:

Nil

Intervention code:

样本总量 Total sample size : 725

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

河南

市(区县):

郑州

Country:

China

Province:

He'nan

City:

Zhengzhou

单位(医院):

河南省人民医院

单位级别:

三级甲等

Institution/hospital:

Henan People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南

市(区县):

郑州

Country:

China

Province:

Henan

City:

Zhengzhou

单位(医院):

河南中医药大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

First Affiliated Hospital of Henan University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南

市(区县):

郑州

Country:

China

Province:

Henan

City:

Zhengzhou

单位(医院):

河南中医药大学第二附属医院

单位级别:

三级甲等

Institution/hospital:

Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

体征记分

指标类型:

主要指标

Outcome:

Physical score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件

指标类型:

次要指标

Outcome:

Adverse event

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清学检测

指标类型:

次要指标

Outcome:

Serological testing

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鼻腔分泌物嗜酸性粒细胞计数

指标类型:

次要指标

Outcome:

Eosinophil count of nasal secretion

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医证候症状记分

指标类型:

主要指标

Outcome:

TCM Syndrome Symptoms Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

AR患儿生活质量评分表

指标类型:

主要指标

Outcome:

AR children's quality of life score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

眼部症状记分

指标类型:

主要指标

Outcome:

Symptoms score of the eye

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

鼻部症状记分

指标类型:

主要指标

Outcome:

Symptom score in nose

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

鼻腔分泌物

组织:

Sample Name:

Nasal secretions

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 3
Min age years
最大 14
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

未使用

Randomization Procedure (please state who generates the random number sequence and by what method):

Not used

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成6个月后,如有合理需求,请联系研究负责人获取研究原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact principal investigator to acquire IPD six months after the trial complete, as long as the acquire is reasonable

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

1.病例记录表 2.excel管理数据

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

1.Case Record Form, CRF 2.excel management data

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above